Brainstorm Cell Therapeutics Inc at Noble Financial Emerging Growth Investor Conference Transcript
Wonderful, thank you very much. Well, it's a real privilege to be here. I know I'm competing with lunch. So I know that's a tall order. Hopefully, you can last for another half-hour before you have your lunch.
My name is Ralph Kern. I'm the Chief Operating Officer and Chief Medical Officer of Brainstorm Cell Therapeutics. We're a publicly traded company. We trade on NASDAQ as BCLI. This is our disclosure as a publicly traded company.
First of all, I want to give you a bit of an introduction to our company. Some of you already know us. Some of you aren't that familiar with what we do. So I wanted to give you a view from 40,000 feet.
We're a clinical stage biotechnology company. We have the potential to be first-in-class as a company that develops and commercializes a cellular therapy for neurodegenerative disease.
And I'll go through the technology in a few slides to give you a bit more depth. But the basic principle is we're using cells not as a cell replacement
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |